These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33946635)

  • 21. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
    Longhitano AP; Slavin MA; Harrison SJ; Teh BW
    Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
    Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
    Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.
    Dufner V; Sayehli CM; Chatterjee M; Hummel HD; Gelbrich G; Bargou RC; Goebeler ME
    Blood Adv; 2019 Aug; 3(16):2491-2498. PubMed ID: 31451445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SOHO State of the Art Updates and Next Questions | Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma.
    Bennett R; Dickinson M
    Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38871556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
    Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
    Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of novel immunotherapies in non-Hodgkin lymphoma.
    Pishko A; Nasta SD
    Transl Cancer Res; 2017 Feb; 6(1):93-103. PubMed ID: 28955654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting.
    Lin Z; Liu L; Li Z; Xu B
    Exp Hematol Oncol; 2023 Apr; 12(1):41. PubMed ID: 37085931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-cell-engaging bispecific antibodies in cancer.
    van de Donk NWCJ; Zweegman S
    Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.
    Tacchetti P; Barbato S; Mancuso K; Zamagni E; Cavo M
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
    Weiss JM; Phillips TJ
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blinatumomab for the treatment of B-cell lymphoma.
    Oak E; Bartlett NL
    Expert Opin Investig Drugs; 2015 May; 24(5):715-24. PubMed ID: 25739952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.
    Ahmed G; Furqan F; Nasrollahi E; Hamadani M
    Expert Rev Anticancer Ther; 2024 Jun; ():1-11. PubMed ID: 38809821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T-cell therapies for lymphoma.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.